Alyeska Investment Group L.P. Invests $106.72 Million in Abbott Laboratories $ABT

Alyeska Investment Group L.P. acquired a new position in Abbott Laboratories (NYSE:ABT - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 1,176,080 shares of the healthcare product maker's stock, valued at approximately $106,717,000. Alyeska Investment Group L.P. owned approximately 0.07% of Abbott Laboratories as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Cornerstone Financial Management LLC bought a new position in Abbott Laboratories in the 4th quarter valued at approximately $25,000. MidAtlantic Capital Management Inc. acquired a new position in Abbott Laboratories in the 4th quarter worth about $25,000. Purpose Unlimited Inc. bought a new position in Abbott Laboratories in the fourth quarter valued at about $25,000. Portfolio Resources Advisor Group Inc. acquired a new stake in shares of Abbott Laboratories during the fourth quarter valued at about $26,000. Finally, Abound Financial LLC bought a new stake in shares of Abbott Laboratories during the fourth quarter worth about $26,000. Institutional investors own 75.18% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have commented on ABT shares. Piper Sandler reiterated an "overweight" rating and issued a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. Robert W. Baird started coverage on shares of Abbott Laboratories in a research report on Wednesday, July 1st. They set an "outperform" rating and a $121.00 target price for the company. Weiss Ratings upgraded shares of Abbott Laboratories from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Thursday, August 6th. TD Cowen lifted their target price on shares of Abbott Laboratories from $115.00 to $135.00 and gave the stock a "buy" rating in a research note on Tuesday, August 25th. Finally, UBS Group decreased their price target on Abbott Laboratories from $135.00 to $125.00 and set a "buy" rating for the company in a report on Tuesday, July 28th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $119.50.

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $108.29 on Friday. The stock has a market cap of $187.38 billion, a price-to-earnings ratio of 35.05, a PEG ratio of 2.02 and a beta of 0.59. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The business has a 50-day simple moving average of $104.43 and a 200 day simple moving average of $100.12. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping analysts' consensus estimates of $1.28 by $0.03. The business had revenue of $12.59 billion during the quarter, compared to analysts' expectations of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business's quarterly revenue was up 13.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, research analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were given a dividend of $0.63 per share. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. Abbott Laboratories's dividend payout ratio (DPR) is presently 81.55%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source